Cite
O'Shea J, Cremona M, Morgan C, et al. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. Oncotarget. 2017;8(49):85120-85135doi: 10.18632/oncotarget.19461.
O'Shea, J., Cremona, M., Morgan, C., Milewska, M., Holmes, F., Espina, V., Liotta, L., O'Shaughnessy, J., Toomey, S., Madden, S. F., Carr, A., Elster, N., Hennessy, B. T., & Eustace, A. J. (2017). A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. Oncotarget, 8(49), 85120-85135. https://doi.org/10.18632/oncotarget.19461
O'Shea, John, et al. "A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib." Oncotarget vol. 8,49 (2017): 85120-85135. doi: https://doi.org/10.18632/oncotarget.19461
O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17. PMID: 29156708; PMCID: PMC5689598.
Copy
Download .nbib